Glenmark gets USFDA nod to Clindamycin Phosphate Gel to treat acne

Written by ruchika Published On 2021-02-11T13:23:44+05:30 | Updated On 11 Feb 2021 1:23 PM IST

Mumbai: Drugmajor, Glenmark Pharmaceuticals Limited, today announced that the company has received final approval by the United States Food & Drug Administration (USFDA) for Clindamycin Phosphate Gel USP, 1%.

The product is a generic version of Cleocin T Gel, 1%, of Pharmacia & Upjohn.

According to IQVIA sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million*.

Glenmark's current portfolio consists of 169 products authorized for distribution in the U.S. marketplace and 42 ANDA's pending approval with the U.S. FDA.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology.

Read also: Glenmark gets USFDA nod for amphetamine sulfate tablets to treat ADHD

glenmark pharmaglenmark pharma newsusfdaclindamycin phosphate gelcleocin t gel

ruchika